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ABSTRACT 
When Justice Harlan penned his opinion in Jacobson v. 
Massachusetts, the landmark case setting the paradigm for when states 
can mandate vaccination, he never imagined the innovative and unique 
vaccines that technology would produce in subsequent decades. Now, as 
new vaccines (such as the human papillomavirus vaccine) emerge that 
fit outside the bounds of precedential case law, state legislatures and 
courts face new territory when determining in what situations the need 
to protect public health via vaccination outweighs an individual’s 
constitutionally-guaranteed rights. This Article explores the current 
process used when assessing vaccines that lay outside the Jacobson 
paradigm. Further, this Article critiques that process and argues that, 
when no set precedent exists, policy should be driven by those who are 
not swayed by social, cultural, religious, political, or economic factors. 
Instead, policy-makers should be those who can craft their decisions 
with an unbiased and scientifically-driven aim, one that will objectively 
weigh the interests of public health and private rights. 
 
INTRODUCTION 
On July 17, 1902, Henning Jacobson, facing a small fine, 
adamantly refused to be vaccinated for smallpox pursuant to a mandate 
ordered by the Board of Health of Cambridge, Massachusetts. 
Trumpeting his rights to “life, liberty and property,” Jacobson battled 
his way to the United States Supreme Court and for two-and-a-half 
years, managed to avoid the vaccine. Then, in December of 1904, the 
Supreme Court found for the Board of Health, holding that the Board’s 
need to protect the public health and safety vindicated the compulsory 
vaccination law. 
With Jacobson began a long history of courts empowering states to 
impose compulsory vaccination laws. Through Jacobson, the Supreme 
Court set a precedent that has provided the framework by which states 
determine when compulsory vaccination is appropriate. Since Jacobson, 
courts have readily upheld state compulsory vaccination laws for 
measles, smallpox, poliomyelitis, rubella, varicella, and other highly 
contagious and deadly diseases. 
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However, states’ authority to create these laws is not always so 
clear. The less danger and imminence a given disease poses to the 
public health, the less necessary a compulsory vaccine is. This 
correlation inspires the question: what types of characteristics must a 
disease have to justify the invasion of an individual’s rights to “life, 
liberty, and property” by mandating a vaccine? With the emergence of 
vaccines made for non-contagious but nonetheless prevalent and 
dangerous diseases (for example, the human papillomavirus (HPV) 
vaccine), the issue of state compulsory vaccination laws has become 
riddled with controversy. Mandating the HPV vaccine has caused a 
particularly heated debate due to the disease’s origins as a sexually 
transmitted infection (STI). 
As vaccines stray further from the Jacobson paradigm, state 
legislatures (which create mandatory vaccination laws) are given 
broader discretion for determining which vaccines should be mandatory. 
This process becomes especially disconcerting when controversial 
vaccines, such as the HPV vaccine, are used as political tools for 
garnering constituent votes. 
Through the lens of the HPV vaccine, this Article discusses the 
process of mandating vaccines and asks who should be making those 
policy decisions. This Article proceeds in seven parts. Parts I, II, and III 
are predominantly dedicated to background and historical information 
critical to evaluating the way compulsory vaccination laws are treated 
today. Part I provides a background of HPV and its vaccine. Part II lays 
out the history of compulsory vaccination laws and describes the current 
paradigm for when mandatory vaccination is justified by public health 
and safety needs. Part III illustrates how the HPV vaccine does not fit 
within the existing paradigm. 
Parts IV through VII transition into discussing how changes to the 
current policy-making process would lead to objective policies not 
swayed by social or economic pressures. Part IV discusses the current 
process for mandating a vaccine. Part V lists the problems with the 
current process, beginning with a discussion of social, cultural, and 
religious pressures faced by state representatives, followed by an 
explanation of how economic pressures play a role in the decision-
making process as well. Part VI advocates for empowering other entities 
with policy-making authority so that they might offer a less-biased 
position on health policy decisions. Lastly, Part VII gives a brief 
introduction to a final consideration – accountability – that should be 
taken into account when deciding who should make these types of 
health policy decisions. 
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This Article makes no conclusions as to who should be making the 
decisions behind compulsory vaccination laws. However, it opens the 
discussion for reworking the process and incorporating other decision-
making entities into the process. As this Article illustrates, the current 
process is too susceptible to social and economic pressures, and health 
policy should be premised on an unbiased, unclouded perspective that 
discerns the true needs of the public regarding safety and health. 
I. HPV AND ITS VACCINE 
HPV infects 6.2 million new people each year just in the United 
States,
1
 making HPV the most common STI in the United States.
2
 
Globally, 50 percent of people who have had sex in their lifetime will 
be infected with HPV.
3
 In one study conducted in the United Kingdom, 
researchers found that even of women with only one lifetime sexual 
partner, 46 percent will acquire HPV within three years of becoming 
sexually active.
4
 While for most, HPV is innocuous, for others, HPV can 
lead to cervical cancer or genital warts. Specifically, HPV strains 16 and 
18 reportedly cause 70 percent of cervical cancer cases and have also 
been attributed to anal, vulvar, vaginal, penile, and urethral cancers.
5
 
HPV strains 6 and 11 cause 90 percent of anogenital warts and have 
also been attributed to recurrent respiratory papillomatosis.
6
 
In June 2006, the United States Food & Drug Administration 
(FDA) announced its approval of Merck’s Gardasil®, the first vaccine 
against HPV,
7
 and in October 2009, the FDA announced its approval of 
GlaxoSmithKline’s Cervarix®, another HPV vaccine.
8
 Gardasil® 
 
1  Lawrence O. Gostin & Catherine D. DeAngelis, Mandatory HPV Vaccination: Public 
Health vs Private Wealth, 297 J. AM. MED. ASS’N 1921, 1921 (2007). 
2  Eileen F. Dunne et al., Prevalence of HPV Infection Among Females in the United 
States, 297 J. AM. MED. ASS’N 813, 813 (2007). 
3  Genital HPV Infection – Fact Sheet, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/std/hpv/stdfact-hpv.htm (last modified Aug. 9, 2012). 
4  Stuart Collins et al., High Incidence of Cervical Human Papillomavirus Infection in 
Women During Their First Sexual Relationship, 109 BJOG 96, 96 (2002). 
5  Gail Javitt, Deena Berkowitz, & Lawrence O. Gostin, Assessing Mandatory HPV 
Vaccination: Who Should Call the Shots? 36 J.L. MED. & ETHICS 384, 385 (Summer 2008). 
6  Id. 
7  Letter from Norman W. Baylor, Director of Office of Vaccines, U.S. Food & Drug 
Administration, to Patrick Brill-Edwards, Director of Worldwide Regulatory Affairs, Merck 
& Co., Inc. (June 8, 2006), available at 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm 
[hereinafter Approval Letter (Gardasil) (June 8, 2006)]. 
8  Letter from Norman W. Baylor, Director of Office of Vaccines, U.S. Food & Drug 
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protects against HPV strains 6, 11, 16, and 18,
9
 while Cervarix® protects 
only against strains 16 and 18.
10
 Although clinical data has not yet 
proven that the HPV vaccine prevents cervical cancer, the HPV vaccine 
is nearly 100 percent effective at guarding against infections associated 
with HPV.
11
 
Subsequent to these FDA approvals, the Centers for Disease 
Control and Prevention (CDC), through its Advisory Committee on 
Immunization Practices (ACIP), issued recommendations regarding 
these vaccines. On June 29, 2006, the ACIP recommended that the HPV 
vaccine be routinely given to girls aged eleven to twelve years old, but 
noted that the vaccine can be given to girls as early as nine years old 
and as late as twenty-six years old.
12
 The CDC has made additional 
recommendations relating to the use of the vaccine by boys. Following 
the FDA’s approval of the vaccine for use in boys ages nine to twenty-
six years old,
13
 the CDC recommended that, similar to young girls, the 
vaccine should be routinely given to boys aged eleven to twelve years 
old, but could also be administered to boys as young as nine years and 
as old as twenty-six.
14
 Professional medical associations, including the 
American Academy of Pediatrics, have recommended use of the vaccine 
for adolescent girls when appropriate.
15
 
 
 
Administration, to Matthew Whitman, GlaxoSmithKlein Biologicals (Oct. 16, 2009), 
available at 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186959.htm 
[hereinafter Approval Letter (Cervarix) (Oct. 16, 2009)]. 
9  Approval Letter (Gardasil) (June 8, 2006), supra note 7. 
10 Approval Letter (Cervarix) (Oct. 16, 2009), supra note 8. 
11 Lawrence O. Gostin, Mandatory HPV Vaccination and Political Debate, 306 J. AM. 
MED. ASS’N, 1699, 1700 (2011). 
12 Press Release, The Centers for Disease Control & Prevention, CDC’s Advisory 
Committee Recommends Human Papillomavirus Virus Vaccination (June 29, 2006), 
available at http://www.cdc.gov/media/pressrel/ 
r060629.htm. 
13 Letter from Wellington Sun, Director of Division of Vaccines, U.S. Food & Drug 
Administration, to Patrick Brill-Edwards, Merck & Co., Inc. (Oct. 16, 2009), available at 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186991.htm 
[hereinafter Approval Letter (Gardasil) (Oct. 16, 2009)]. 
14 Press Briefing Transcript, ACIP Recommends All 11-12 Year-Old Males Get 
Vaccinated Against HPV, CTRS. FOR DISEASE CONTROL & PREVENTION (Oct. 25, 2011), 
available at http://www.cdc.gov/media/releases/2011/t1025_hpv_12yroldvaccine.html. 
15 Gostin, supra note 11, at 1700. 
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II.  POLICE POWERS: THE ESTABLISHED PARADIGM 
Since the FDA approved Gardasil®, forty-one state legislatures 
have proposed HPV vaccine-related legislation.
16
 Only Texas, Virginia, 
and the District of Columbia have successfully imposed state 
mandates.
17
 Virginia, for example, requires all girls to have received at 
least the first dose of the HPV vaccine before they enter the sixth 
grade.
18
 Although other states do not have mandatory vaccination laws, 
they have implemented public education, free vaccination, and other 
programs to promote the HPV vaccine.
19
 
States have the authority to implement compulsory vaccination 
legislation through constitutionally-provided police powers.
20
 Through 
police powers, states can create “such reasonable regulations established 
directly by legislative enactment as will protect the public health and the 
public safety.”
21
 It was first established that state compulsory 
vaccination laws were protected by police powers in the landmark case 
Jacobson v. Massachusetts.
22
 In Jacobson, the Supreme Court upheld a 
Massachusetts law mandating smallpox vaccination where such 
vaccination was “necessary for the public health or the public safety.”
23
 
In Zucht v. King, the Supreme Court affirmed “that it is within the 
police power of a state to provide for compulsory vaccination” when 
required for public health.
24
 
Certainly, precedent has firmly established that where states have a 
legitimate public health goal, states can exercise police powers to create 
compulsory vaccination laws. But what constitutes a legitimate public 
health goal? 
The decision in Jacobson highlighted that legitimate public health 
goals are those that protect the community as a whole. As the Court 
stated in Jacobson, “[t]here are manifold restraints to which every 
person is necessarily subject for the common good.”
25
 For vaccines, 
underlying this need to serve the common good is a concept called 
 
16 Id. 
17 Id. The Texas law, however, was subsequently revoked. 
18 VA. CODE ANN. § 32.1 (2007). 
19 Gostin, supra note 11, at 1700. 
20 U.S. CONST. amend. X. 
21 Jacobson v. Massachusetts, 197 U.S. 11, 25 (1905). 
22 Id. 
23 Id. at 27. 
24 Zucht v. King, 260 U.S. 174, 176 (1922). 
25 Jacobson, 197 U.S. at 26 (emphasis added). 
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“herd immunity,” which is defined as: 
[w]hen a sufficiently large proportion of individuals in a community 
is immunized, those persons serve as a protective barrier against the 
likelihood of transmission of the disease in the community, thus 
indirectly protecting those who are not immunized and those who 
received the vaccine but are not protected (vaccine failures).
26
 
In other words, even when some individuals are not immunized, disease 
transmission is hampered when the overall community is immunized.
27
 
For a disease like smallpox (the subject of Jacobson), the benefits 
of compulsory vaccination are immediately apparent because 
community vaccination contributes to the establishment of herd 
immunity. Smallpox is highly contagious because it is readily 
transmitted through face-to-face contact and contact with bodily fluids.
28
 
Although rarely, smallpox can also be transmitted through air in 
enclosed settings, such as buildings, buses, and trains.
29
 Once infected, 
the disease is largely untreatable as soon as symptoms emerge (one to 
four days after exposure), and the disease can be fatal.
30
 Further, 
smallpox can only be transmitted between humans; there are no insect 
or animal hosts.
31
 Accordingly, without human hosts, the disease cannot 
be transmitted. Indeed, the efforts to eradicate smallpox through 
compulsory vaccination have been successful with one hundred percent 
eradication since 1977.
32
 
State eradication programs for diseases with features similar to 
those of smallpox have likewise been found to promote public health 
and safety because they contribute to herd immunity. Various courts 
have upheld state compulsory vaccination laws for measles, diphtheria 
toxoid, poliomyelitis, rubella, mumps, and other diseases.
33
 Measles, for 
example, like smallpox, is highly contagious with the estimate that if 
 
26 Kevin M. Malone & Alan R. Hinman, Vaccination Mandates: The Public Health 
Imperative and Individual Rights, in LAW IN PUBLIC HEALTH PRACTICE 262, 264 (Richard A. 
Goodman et al. eds., 2003). 
27 Margaret J. Kochuba, Public Health vs. Patent Rights: Reconciling Informed Consent 
with HPV Vaccination, 58 EMORY L.J. 761, 765 (2009). 
28 Smallpox Disease Overview, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://emergency.cdc.gov/agent/smallpox/overview/disease-facts.asp (last modified Dec. 30, 
2004). 
29 Id. 
30 Smallpox, A.D.A.M. MED. ENCYCLOPEDIA, 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002332/ (last visited Nov 30, 2012). 
31 Smallpox Disease Overview, supra note 28. 
32 Malone & Hinman, supra note 26, at 265. 
33 Id. at 270. 
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one person contracts measles, ninety percent of people close to that 
individual will also get infected.
34
 Further, measles can be highly fatal; 
today, 164,000 people per year die of measles, despite immensely 
successful eradication programs.
35
 The disease can only be transmitted 
by humans.
36
 The measles vaccine was introduced in 1963, and by 1983, 
all states had mandatory measles vaccine laws.
37
 One court found that, 
“given the characteristics of measles,” the Arizona State Health 
Department was authorized to adopt measures, including prohibiting 
unvaccinated children from attending school, to protect the public from 
a measles outbreak.
38
 
However, not all diseases fit so neatly into the category of diseases 
that warrant mandatory vaccination laws. Not all diseases are so highly 
contagious, highly fatal, or narrowly transmitted (e.g. transmitted only 
by humans) as smallpox or measles and therefore, cannot be justified by 
the concept of herd immunity. As courts are presented with such 
diseases, they must stray from the paradigm established by Jacobson to 
find justification for compulsory vaccination laws established to prevent 
these diseases. 
In Boone v. Boozman, the court was presented with such a decision 
when a plaintiff brought suit alleging that mandatory hepatitis B 
vaccination was unconstitutional.
39
 Although hepatitis B is fatal in about 
one percent of cases and highly contagious,
40
 it is distinct from measles 
or smallpox in that it is most commonly transmitted by affirmative 
action on the part of the infected, e.g. unprotected sex or intravenous 
drug use.
41
 Nonetheless, the court found that, 
[although] Hepatitis B may not be airborne like smallpox . . . this is 
not the only factor by which a disease could be judged dangerous. 
Hepatitis B is spread by bodily fluids; the virus is “fairly hearty and 
 
34 Transmission of Measles, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/measles/about/transmission.html (last modified Aug. 31, 2009). 
35 Overview of Measles Disease, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/measles/about/overview.html (last modified Apr. 13, 2012). 
36 Transmission of Measles, supra note 34. 
37 Malone & Hinman, supra note 26, at 271. 
38 Maricopa Cty. Health Dep’t v. Harmon, 156 Ariz. 161, 166 (Ariz. Ct. App. 1987). 
39 Boone v. Boozman, 217 F. Supp. 2d 938, 952-54 (E.D. Ark. 2002). 
40 Hepatitis B, A.D.A.M. MED. ENCYC., 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001324/ (last visited Nov. 30, 2012). 
41 Hepatitis B, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/hepatitis/chooseb.htm (last modified Apr. 1, 2008). 
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can survive on surfaces, door knobs, et cetera, for up to a month.”
42
 
The court further held that “[i]mmunization of school children against 
hepatitis B has a real and substantial relation to the protection of the 
public health and the public safety.”
43
 
Similarly, tetanus is highly fatal (leading to death in one out of ten 
cases
44
) but is not at all transmittable between people. Rather, tetanus is 
caused by the bacteria C. Tetani that enters the body through injuries or 
wounds, hence its association with rusty nails and other piercing metal 
objects.
45
 Thus, herd immunity is a complete impossibility for tetanus, 
and yet, forty-nine states mandate tetanus vaccination,
46
 the reason 
perhaps being the grisly consequences of contracting tetanus. Tetanus 
“do[es] not fit the ‘paradigm’ for compulsory vaccination . . . yet 
declaring the tetanus mandate laws unconstitutional under Jacobson 
could lead to needless cases of the gruesome lockjaw caused by the 
disease.”
47
 Through hepatitis B and tetanus, courts have opened the door 
to state mandates for vaccines that fit outside of the Jacobson paradigm. 
III. THE HPV VACCINE:STEPPING OUTSIDE THE PARADIGM 
No court has yet had the opportunity to review mandatory HPV 
vaccine laws for their constitutionality. In March 2010, a pro se plaintiff 
brought suit against the United States Government, challenging the 
distribution of the HPV vaccine in public schools in the District of 
Columbia.
48
 The case was successfully dismissed in favor of the 
Government for lack of standing.
49
 
Despite the dearth of common law, when assessing the 
characteristics of HPV, it is evident that HPV more closely aligns with 
hepatitis B and tetanus, rather than with smallpox or measles. Thus, 
HPV falls outside of the Jacobson paradigm that protects state 
compulsory vaccination laws justified by herd immunity. 
 
42 Boone, 217 F. Supp. 2d at 954 (internal quotations omitted). 
43 Id. 
44 Tetanus (Lockjaw) Vaccination, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/vaccines/vpd-vac/tetanus/default.htm#disease (last modified Jan. 19, 
2012). 
45 Tetanus, A.D.A.M. MED. ENCYC., 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001640/ (last visited Nov. 30, 2012). 
46 Malone & Hinman, supra note 26, at 270. 
47 Case Note, Toward a Twenty-First-Century: Jacobson v. Massachusetts, 121 HARV. 
L. REV. 1820, 1838 (2008). 
48 Ndaba v. Obama, 697 F. Supp. 2d 75, 76 (D.C. 2010). 
49 Id. at 78. 
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A. Contagiousness 
Unlike measles and smallpox, HPV is not easily communicable. 
The virus resides in an individual’s epithelial (a.k.a. skin) cells, 
particularly in mucous membranes, such as the genital areas, and is 
transmitted by contact with the infected area.
50
 This means that HPV is 
largely transmitted by affirmative actions, namely vaginal, oral, and 
anal sex.
51
 Contagion, in and of itself, does not prevent a disease from 
warranting compulsory vaccination laws, as could be seen with hepatitis 
B and tetanus. However, unlike hepatitis B and tetanus, HPV is not a 
robust virus that can reside on surfaces or doorknobs. HPV is relegated 
to skin cells and thus, is truly limited in its ability to transmit. 
B. Fatality 
Although HPV is quite prevalent, genital warts, cervical cancer, 
and other types of cancers only occur in ten percent of HPV cases.
52
 Of 
the diseases caused by HPV, cervical cancer is the most common with 
twelve thousand new cases of cervical cancer each year in the United 
States.
53
 A study conducted in 2007 (the most recent data available) 
showed that four thousand women die each year from cervical cancer,
54
 
equating to a morbidity rate of 2.4 deaths per one hundred thousand 
women.
55
 To put that in context, in the three years before the measles 
vaccine was licensed in 1963, the average annual morbidity for children 
afflicted with measles in the United States was over five hundred 
thousand.
56
 Further, incidence rates of cervical cancer continue to fall 
due to the development and greater availability of screening and 
treatment services. Since the 1960s, cervical cancer incidence rates have 
 
50 Debbie Bridges, Information About the Human Papillomavirus (HPV), WEBMD, 
http://www.webmd.com/sexual-conditions/hpv-genital-warts/hpv-virus-information-about-
human-papillomavirus (last viewed Nov. 13, 2012). 
51 Id. 
52 Genital HPV Infection – Fact Sheet, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/std/hpv/stdfact-hpv.htm (last modified Aug. 9, 2012). 
53 Id. 
54 Cervical Cancer Statistics, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/cancer/cervical/statistics/index.htm (last modified Apr. 30, 2012) 
(citing U.S. Cancer Statistics Working Group, United States Cancer Statistics: 1999–2007 
Incidence and Mortality Web-based Report, CTRS. FOR DISEASE CONTROL & PREVENTION, 
available at http://www.cdc.gov/uscs (last viewed Nov. 13, 2012)). (full site) 
55 SEER Stat Fact Sheets: Cervix Uteri, NAT’L CANCER INST., 
http://seer.cancer.gov/statfacts/html/cervix.html (last viewed Nov. 13, 2012). 
56 Malone & Hinman, supra note 26, at 266. 
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fallen by seventy-five percent because cytology screening (the “Pap 
smear”) was introduced and has become standard in women’s health 
care.
57
 
C. Modes of Transmission 
Like measles and smallpox, HPV is transmitted between humans. 
However, thus far, no state mandates the HPV vaccine for men, despite 
the FDA having approved the vaccine for men in December 2010.
58
 For 
herd immunity to be successful, immunization levels must reach a 
specified threshold to protect the total number of susceptible 
individuals.
59
 As an example, a study in Brazil showed that nearly 100 
percent immunization of infants, coupled with subsequent yearly 
vaccination of these infants for eight to nine years, was necessary to 
interrupt the transmission of poliomyelitis there.
60
 While there is no 
indication of what immunization level is required for eradication of 
HPV to be successful, the lack of any mandates for men would at the 
very least make the eradication process slower, if not make eradication 
entirely impossible. 
D. Summary 
On the other hand, HPV hosts other characteristics that suggest that 
a compulsory vaccination law might be necessary. First, HPV is highly 
prevalent with at least fifty percent of sexually active men and women 
contracting it in their lifetime.
61
 Second, the disease is asymptomatic for 
ninety percent of people,
62
 which means that people can transmit HPV 
during sexual intercourse without even knowing that they carry the 
virus. Lastly, because the virus resides in skin cells that may not be 
covered by a condom, individuals can contract HPV even when they 
think they are engaging in “safe sex.”
63
 
 
57 Vivien Davis Tsu, Overcoming Barriers and Ensuring Access to HPV Vaccines in 
Low-Income Countries, 35 AM. J.L. & MED. 401, 402 (2009). 
58 Letter from Wellington Sun, Director of Division of Vaccines, U.S. Food & Drug 
Administration, to Patrick Brill-Edwards, Merck & Co., Inc. (Dec. 22, 2010), available at 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm238074.htm 
[hereinafter Approval Letter (Gardasil) (Dec. 22, 2010)]. 
59 T. Jacob John & Reuben Samuel, Herd Immunity and Herd Effect: New Insights and 
Definitions, 16 EUR. J. OF EPIDEMIOLOGY 601, 602 (2000). 
60 Id. 
61 Genital HPV Infection – Fact Sheet, supra note 52. 
62 Id. 
63 Bridges, supra note 50. 
12 SETON HALL LEGISLATIVE JOURNAL [Vol. 37:1 
Despite these characteristics, HPV does not lend itself to a 
mandatory vaccination law to the same extent that measles or smallpox 
does. Moreover, the HPV vaccine does not lend itself to a mandatory 
vaccination law even to the same extent that hepatitis B or tetanus does. 
Thus, the question then becomes, when a disease falls outside of the 
Jacobson paradigm and is not protected by the exceptions provided in 
Boone, who decides whether the vaccine should be mandatory? 
IV. VACCINES: FROM RECOMMENDING TO REQUIRING 
Understanding the current process for making a vaccine mandatory 
is necessary for evaluating who should be driving the process. While 
mandating a vaccine may seem like a singular decision, the entire 
process involves a series of discretionary choices from a variety of 
government agencies and representatives, starting with the FDA and 
ending with state legislatures. 
Vaccines, like any other medical product, must first go through 
regulatory approval by the FDA. The FDA is a government agency 
within the Department of Health and Human Services, and it is 
“responsible for protecting the public health by assuring the safety, 
efficacy and security of . . . drugs, biological products, [and] medical 
devices . . . .”
64
 Under the Federal Food, Drug & Cosmetics Act, the 
FDA holds the authority to review vaccines for safety and efficacy 
before the maker of a vaccine is permitted to distribute the vaccine to 
the public.
65
 Upon review, the FDA will either approve or deny a new 
vaccine. 
Once a vaccine has been approved, the Centers for Disease Control 
and Prevention (the “CDC”) establishes written recommendations for 
the administration of vaccines to the general public. The CDC is a 
federal agency under the Department of Health and Human Services, 
and a large part of its mission is to prevent disease.
66
 The CDC 
specifically addresses vaccines through its Advisory Committee on 
Immunization Practices (ACIP). The ACIP consists of fifteen 
immunology experts (and additional non-voting members and liaisons) 
who advise the Secretary of the U.S. Department of Health and Human 
 
64 What We Do, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/aboutfda/whatwedo/default.htm (last modified June 19, 2012). 
65 42 U.S.C. § 262 (2012). 
66 Vision, Mission, Core Values, and Pledge, CTRS. FOR DISEASE CONTROL & 
PREVENTION, http://cdc.gov/about/organization/mission.htm (last modified Jan. 11, 2010). 
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Services, the Assistant Secretary for Health, and the CDC.
67
 
While one aspect of the CDC’s mission is to prevent disease, 
another aspect is to “develop and advocate sound public health 
policies.”
68
 As such, the CDC’s recommendations are often used by 
states to develop legislation. In fact, while the CDC’s recommendations 
are non-binding, the “power and prestige of the CDC and other 
administrative heavy artillery easily intimidates state legislators and 
even health care professionals who might otherwise deviate from the 
official path.”
69
 
After the CDC issues a recommendation regarding a vaccine, state 
representatives may propose a bill to state legislatures that will make the 
vaccine mandatory. Alternatively, some state legislatures grant authority 
to regulatory bodies, such as a Board of Health.
70
 In some cases, state 
governors issue executive orders, which subsequently must pass through 
the state legislature. In any case, the bill must ultimately pass through 
the state legislature, which holds the power to mandate a vaccine 
through its constitutionally-provided police powers.
71
 Police powers 
give states the authority to create “such reasonable regulations 
established directly by legislative enactment as will protect the public 
health and the public safety.”
72
 
V. SOCIAL, ECONOMIC, AND OTHER PRESSURES:  
PROBLEMS WITH THE CURRENT METHOD 
Currently, state representatives (whether state legislators or 
governors) are driving the policies behind mandatory vaccination. Of 
course, the nature of state representatives is that they are elected by their 
state constituents, which draws concern when assessing how effective 
representatives are at determining the best interests of the general public 
in terms of health and safety. A decision incentivized by social or 
economic pressures may not accurately reflect the best interests of the 
public. 
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69 KURT LINK, THE VACCINE CONTROVERSY: THE HISTORY, USE, AND SAFETY OF 
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70 Richard Hughes, IV, Using Law, Policy, and Research to Improve the Public’s 
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72 Jacobson, 197 U.S. at 25. 
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A. Social, Cultural, and Religious Pressures 
State representatives may seek to represent the interests of their 
constituents; however, to begin with, the general public is largely 
uninformed when it comes to HPV. A national survey conducted in 
2000 found that less than two percent of Americans know that HPV is 
an STI.
73
 Although public knowledge about HPV has increased since the 
introduction of the vaccine, knowledge is nonetheless limited, and the 
majority of women are still unaware of the link between HPV and 
cervical cancer.
74
 As a result, the public depends on sources like health 
agencies, pharmaceutical companies, special interest groups, the media, 
and the internet for information, and these sources are largely 
conflicting and furthermore, biased.
75
 On that point, because non-profit 
organizations, the CDC, and public health organizations have limited 
budgets and resources, the vaccine manufacturers (those with the 
biggest budgets) are best able to reach audiences, leaving public 
education in the hands of Merck and GlaxoSmithKline, companies that 
have been accused of heavily skewing the data.
76
 
To add to the misperceptions surrounding HPV, HPV is a largely 
stigmatized disease, mostly because it elicits the taboo topic of sexual 
health.
77
 In one study, participants were asked to list words they 
associated with sexually transmitted diseases, and the most common 
words named were promiscuity, infidelity, shame, embarrassment, guilt, 
and divorce.
78
 In the United States, there is a strong belief that 
mandating an HPV vaccine will encourage young girls to become 
sexually active at an early age and will encourage sexual promiscuity.
79
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In addition to stigmatizing the disease, the public has stigmatized 
the vaccine itself. There is a popular misperception that the vaccine is 
unsafe, was not satisfactorily tested before FDA approval, and leads to 
afflictions such as autism.
80
 On the contrary, the safety profile for the 
HPV vaccine is quite robust. Clinical trials have been conducted with 
over 59,000 participants,
81
 and as of January 2010, an estimated 28 
million doses of Gardasil® alone had been administered in the United 
States.
82
 As of June 2011, the only vaccine side effects reported to the 
FDA were minor (dizziness, fainting, headache, nausea, and injection-
site reactions), and autism and other types of mental and development 
disorders have never been reported.
83
 
Representatives making decisions regarding the HPV vaccine face 
pressure due to these public perceptions. In February 2007, Governor 
Rick Perry issued an executive order and singlehandedly mandated the 
HPV vaccine in Texas for girls entering the sixth grade in 2007.
84
 Even 
before Governor Perry introduced the action, the National Vaccine 
Information Center (NVIC), a non-profit organization that has been 
described as “the most powerful anti-vaccine organization in 
America,”
85
 had begun its campaign to thwart implementation of a 
mandatory HPV vaccine.
86
 The NVIC based its campaign on the premise 
that Merck had failed to prove the safety of Gardasil®.
87
 It was 
successful, and only a few months later, in May 2007, the Texas 
legislature voted to overturn Governor Perry’s executive order.
88
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Even recently, as Governor Perry ran for the Republican 
Presidential ticket, his campaign reopened old wounds. While Governor 
Perry defended his decision to mandate the vaccine in 2007, his 
opponents fueled common false beliefs and perpetuated the HPV 
vaccine stigma. For example, during the Republican Presidential debate 
held September 12, 2011, Republican Presidential candidate Michele 
Bachmann argued, 
to have innocent little 12-year-old girls be forced to have a 
government injection through an executive order is just flat out 
wrong . . . little girls who have a negative reaction to this potentially 
dangerous drug don’t get a mulligan. They don’t get a do-over. The 
parents don’t get a do-over.
89
 
One day later, in an interview on the Today Show, Ms. Bachmann 
stated, 
Well, I will tell you that I had a mother last night come up to me here 
in Tampa, Florida after the debate and tell me that her little daughter 
took that vaccine, that injection, and she suffered from mental 
retardation thereafter. It can have very serious side effects.
90
 
Representatives seeking to please constituents may play into these 
social and cultural beliefs just to get a vote, and in fact, research shows 
that their strategy may not be entirely without merit. Voters are more 
likely to vote according to their moral beliefs because of the low cost of 
voting and the absence of any significant effect on the voter’s interests.
91
 
Furthermore, because HPV relates to sexual health, it may get lumped 
with other single-issue voting topics, such as abortion. 
B. Economic and Political Pressures 
When issuing his executive order, Governor Perry faced pressures 
just as pervasive as social, cultural, and religious pressures; he 
confronted economic pressures from the patent-holders, namely Merck. 
The pharmaceutical and biotechnology industries are notoriously strong 
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lobbyists, and so their influence on law-making cannot be understated.
92
 
According to the Center for Responsive Politics, the drug lobby spent 
over $2.5 billion in lobbying funds between 1998 and 2012.
93
 This 
figure surpasses any other industry by more than 700 million dollars.
94
 
The HPV vaccine is unique because both vaccines available 
(Gardasil® and Cervarix®) are still under patent, which provides the 
manufacturers of these drugs a near monopoly on the market and 
permits the manufacturers to charge high prices. Both vaccines require 
three doses.
95
 For children, the CDC can provide Gardasil® at a cost of 
$98.60 per dose and Cervarix® at a cost of $96.08 per dose, while the 
private sector cost is $135.45 per dose for Gardasil® and $128.75 per 
dose for Cervarix®.
96
 
Notably, there are no generic versions of the HPV vaccine in 
development due to previously-existing rules that prohibited the 
creation of follow-on biologics (which includes vaccines). The Patient 
Protection and Affordable Care Act laid out instructions for the 
Secretary of the Department of Health and Human Services and the 
FDA to create a follow-on biologics regulatory pathway.
97
 The creation 
of a generic HPV vaccine would ultimately reduce the cost of the 
vaccine, but until then, patients are subject to high prices. 
Due to this near monopoly on the market, Merck and 
GlaxoSmithKline have great incentive to encourage states to pass 
compulsory vaccination laws, and in fact, Merck has been actively 
lobbying for state compulsory laws. According to records from New 
York’s Temporary State Commission on Lobbying, Merck spent almost 
400 thousand dollars between 2003 and 2006 on lobbying for 
Gardasil®.
98
 The CDC has also implied that vaccine manufacturers have 
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heavily influenced the adoption of mandatory HPV laws.
99
 According to 
Governor Perry, Merck only donated 5,000 dollars to his gubernatorial 
campaign at the time he issued the executive order mandating the HPV 
vaccine in Texas.
100
 In reality, Merck donated $28,500 to his 
gubernatorial campaign and $377,500 to the Republican Governors 
Association,
101
 an organization for which Governor Perry served as 
Chairman and whose mission it is to help elect Republican candidates to 
governorships throughout the country.
102
 
Despite this apparent conflict of interest, Governor Perry had other, 
less controversial economic pressures that weighed towards the passage 
of a compulsory vaccination law. The costs of HPV-related diseases are 
staggering, with an estimated $4 billion in annual direct medical costs 
for the prevention and treatment of genital warts and cervical cancer.
103
 
That $4 billion is comprised of the following estimates of annual direct 
medical costs: cervical cancer ($300-400 million), cervical 
intraepithelial neoplasia ($700 million-$2.3 billion), anogenital warts 
($200 million), and routine cervical cancer screening ($2.3 billion).
104
 
The total excludes lost productivity costs and medical costs attributed to 
other HPV-related diseases, such as anal, penile, vaginal, and vulvar 
cancers.
105
 
Even with such high costs related to the treatment and prevention 
of cervical cancer and genital warts, drug industry lobbying reflects 
poorly on state representatives’ ability to make unbiased decisions when 
it comes to public health.
106
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VI.  UNBIASED ENTITIES: MOVING TOWARDS AN 
OBJECTIVE DECISION-MAKING PROCESS 
State representatives are subject to an immense amount of pressure 
that draws into question their ability to effectively make decisions 
regarding the public’s health and safety. When presented with vaccines 
that fall outside of the Jacobson paradigm, is it best to defer policy-
making decisions to other more objective entities? The FDA, the CDC, 
the ACIP, and professional medical associations could potentially fill 
that role; however, each entity faces its own set of political pressures 
and areas of vulnerability that make it arguably unsuitable for such 
policy-making. 
A. The FDA 
When considering other entities that could assume the 
responsibility of developing compulsory vaccination policies, the FDA 
is an immediately apparent choice. The FDA is historically a science-
based agency
107
 and was originally responsible for the HPV vaccine’s 
approval. The FDA has followed Merck and GlaxoSmithKline through, 
collectively, the administration of over 59,000 doses of the HPV 
vaccine.
108
 It has been intimately involved in the approval of package 
inserts and patient information pamphlets.
109
 The FDA receives and 
reviews any and all adverse side effects reports.
110
 In summary, the FDA 
holds an immense amount of information about the HPV vaccine and at 
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least from a purely scientific point of view, could formulate a 
conclusion regarding whether it should be mandatory. 
Yet despite the FDA’s wealth of knowledge, the FDA is not 
without bias. FDA agents lack any sort of sustained relationship with 
consumers but regularly interact with pharmaceutical and biotechnology 
manufacturers.
111
 This close relationship with the pharmaceutical and 
biotechnology industries is all the more true because of the “revolving 
door” which rotates FDA employees from the FDA to the 
pharmaceutical and biotechnology industries and back again.
112
 
To make matters worse, senior appointees to FDA offices are 
typically appointed for political reasons, and as such, senior appointees 
marginalize the opinions of FDA scientists in exchange for the political 
opinions of their appointers.
113
 Most recently, FDA Commissioner 
Margaret Hamburg substituted the opinion of FDA scientists for the 
wishes of Kathleen Sebelius, the Secretary of the Department of Health 
and Human Services, regarding Plan B, an emergency contraceptive.
114
 
The Center for Drug Evaluation and Research (CDER), a division 
within the FDA, reviewed Plan B to determine if it was safe as an over-
the-counter product for girls under seventeen years of age.
115
 CDER 
determined that Plan B was in fact safe for those purposes.
116
 
Dr. Hamburg agreed, stating, 
I reviewed and thoughtfully considered the data, clinical information, 
and analysis provided by CDER, and I agree with the Center that 
there is adequate and reasonable, well-supported, and science-based 
evidence that Plan B One-Step is safe and effective and should be 
approved for nonprescription use for all females of child-bearing 
potential.
117
 
However, after receiving a memorandum from Secretary Sebelius 
disapproving of CDER’s findings, Dr. Hamburg ordered Plan B to 
remain prescription-only for girls under seventeen years old.
118
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The Plan B decision serves as a pointed example of how the FDA 
is not immune to pressure from politicians and may not be the wholly 
scientific authority it espouses itself to be. In addition, even if the FDA 
had the authority to do so, determining whether a vaccine should be 
mandatory may be outside the bounds of what is feasible for it both in 
terms of its resources and its expertise. 
B. The CDC and the ACIP 
The CDC and ACIP stand in a similar position as the FDA when it 
comes to the broad scope of knowledge they hold regarding the HPV 
vaccine. If anything, the CDC’s knowledge is even more comprehensive 
than the FDA’s because the CDC has a thorough understanding of the 
epidemiological context in which the HPV vaccine lies. 
First, the CDC aims to “monitor health, detect and investigate 
health problems, [and] conduct research to enhance prevention.”
119
 
When it comes to vaccines, maintaining a regularly and constantly 
updated database that catalogues the distribution and coverage of 
vaccines is critical to this goal. The CDC collects vaccination 
information by two methods: the National Immunization Survey (NIS) 
and school and childcare vaccination surveys.
120
 
The NIS first began in 1994 to track the immunization rates of 
diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, rubella, 
and Haemophilus Influenza type B (whooping cough).
121
 Starting in 
2006, the NIS created an on-going survey of HPV immunization 
coverage among teens aged thirteen to seventeen years old.
122
 The 
survey provides annual data from 2006 to 2011.
123
 The NIS has also put 
together an adult study, which analyzes why some adults have chosen to 
receive the HPV vaccine and why others have not.
124
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The school and childcare vaccination surveys are a second data-
collection method employed by the CDC. For those states that have 
enacted compulsory vaccination laws, the CDC has asked those states to 
report on vaccination coverage.
125
 As states review and assess 
vaccination coverage in their own mandatory vaccination programs, 
they report those findings to the CDC.
126
 These reports are mandatory 
for any schools and childcare facilities that receive grants from the 
CDC.
127
 Between the NIS and the school and childcare vaccination 
surveys, the CDC has gathered extensive information about the 
distribution and coverage of the HPV vaccine since its approval by the 
FDA. 
Second, the CDC has developed the Vaccine Management 
Business Improvement Project (VMBIP). Through VMBIP, the CDC 
performs a “top-to-bottom” assessment of the entire national 
vaccination program, including everything from vaccine ordering to 
vaccine distribution.
128
 The CDC has partnered with state and local 
governments to review and improve the current vaccination process.
129
 
Through this program, the CDC has become familiar with HPV vaccine 
supply, demand, and coverage and has aided states to develop 
streamlined HPV vaccine management programs.
130
 
Third, the CDC has the biggest representation from various 
medical, scientific, and industry organizations and associations. 
Although the ACIP only consists of fifteen voting members, the 
committee receives input from other non-voting members.
131
 The voting 
members consist almost entirely of doctors, lawyers, and nurses who 
specialize in immunology and currently serve as professors at various 
universities across the country.
132
 The Ex Officio members, on the other 
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hand, are federal agency representatives.
133
 Moreover, the ACIP has 
liaison representatives from numerous medical associations and 
organizations, as well as the biotechnology and pharmaceutical 
industries.
134
 While not all of these members are voting members, at 
least the ACIP involves the opinions of experts from a broad spectrum 
of medical fields. 
Lastly, the CDC already has as part of its mission to “develop and 
advocate sound public health policies.”
135
 Specifically, the ACIP’s role 
is to 
provide advice that will lead to a reduction in the incidence of 
vaccine preventable diseases in the United States, and an increase in 
the safe use of vaccines and related biological products. The 
Committee develops written recommendations for the routine 
administration of vaccines to children and adults . . . The ACIP is the 
only entity in the federal government that makes such 
recommendations.
136
 
Thus, the CDC and ACIP are already equipped with the expertise and 
capabilities to make recommendations regarding vaccine mandates. 
Despite the CDC and ACIP’s qualifications, they are subject to the 
same criticisms as the FDA. To begin with, the voting members of the 
ACIP are exposed to political pressure because they are all elected by 
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the Secretary of the Department of Health and Human Services.
137
 In 
addition, the CDC holds tight relationships with pharmaceutical and 
biotechnology companies. To provide vaccines at discounted prices to 
state and city immunization programs, the CDC enters into contracts 
with vaccine manufacturers.
138
 In fact, the CDC is the largest purchaser 
and distributor of vaccines.
139
 Although the CDC provides dozens of 
different vaccines to immunization programs, these vaccines are 
manufactured by a relatively small number of companies: 
GlaxoSmithKline, MassBiologics, MedImmune, Merck, Novartis, 
Pfizer, and Sanofi Pasteur.
140
 In effect, the CDC’s dedication to the 
success of the immunization programs it assists may in some ways also 
serve as its Achilles’ heel because it depends so heavily on these 
pharmaceutical and biotechnology companies to provide vaccines at a 
discounted rate. 
The CDC and ACIP have been criticized in particular because of 
their relationship with Merck and the HPV vaccine. At the time the 
FDA approved the use of Gardasil®, Merck had only carried the vaccine 
through three-and-a-half years of clinical trials with 12,000 patients, 
which is a relatively small number.
141
 Many assailed the vaccine for not 
being supported by sufficient safety and efficacy data, and yet, in the 
same month as the FDA gave its stamp of approval, so did the CDC and 
ACIP.
142
 Without addressing the low amount of clinical testing, the CDC 
recommended that the vaccine be “routinely given to girls when they 
are 11-12 years old.”
143
 
To add fuel to the fire, on January 25, 2010, Dr. Julie Gerberding 
became President of Merck Vaccines after having served as the Director 
of the CDC from 2002 to 2009.
144
 Dr. Gerberding’s tenure as CDC 
Director included the time period that the CDC reviewed and 
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recommended the HPV vaccine. Her move to “big pharma” prompted a 
flurry of charged and aggressive articles and blogs accusing Dr. 
Gerberding of having been in the back pocket of Merck during her 
entire time as CDC Director.
145
 
Whether or not the accusations against Dr. Gerberding are true, 
certainly the CDC is not a stranger to the concept of the “revolving 
door,” just as is true for the FDA. Unlike the FDA, however, the CDC 
has this additional interdependent relationship with the pharmaceutical 
and biotechnology industries, which draws further skepticism to the 
CDC’s ability to remain an unbiased decision-making entity. 
C. Professional Medical Associations 
Until recently, professional medical associations did not make 
recommendations regarding the use of various drugs, biologics, and 
other medications.
146
 However, it is not entirely out of the question that 
perhaps they should. After all, physicians ultimately should care about 
patient health and safety above all else. The mission statements of most 
professional medical associations echo this sentiment. The American 
Academy of Pediatrics “dedicate[s] their efforts and resources to the 
health, safety and well-being of infants, children, adolescents and young 
adults.”
147
 Likewise, the American Medical Association “promote[s] the 
art and science of medicine and the betterment of public health.”
148
 This 
commitment to the public health provides professional medical 
associations with a uniquely objective perspective. 
Because professional medical associations have only recently 
started making vaccine recommendations, when state laws mandating 
the HPV vaccine first started being proposed, state legislatures were 
doing so without physician input.
149
 Now, many prominent professional 
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medical associations, including the American Academy of Pediatrics, 
the American Academy of Family Physicians, and the American 
College of Physicians, have recommended the administration of the 
vaccine to females aged eleven to twelve years old.
150
 
However, these professional medical associations largely shy away 
from making recommendations regarding state mandates. The exception 
is the American Medical Association, which allows physician 
commentators to contribute to its Journal of the American Medical 
Association (JAMA). It should be noted that the editorials published in 
JAMA do not represent the opinions of the American Medical 
Association; however, they do offer insight into the thoughts and 
perspectives of individual physicians. For example, one article lauded 
the potential of the HPV vaccine but strongly advised against 
compulsory vaccination laws, calling them a “last resort.”
151
 
Physician perspectives given in JAMA vary greatly,
152
 and this 
accurately reflects the fragmented opinions of physicians in general 
regarding the HPV vaccine. In a study conducted by Medimix 
International, a healthcare marketing research company, 57 percent of 
physicians thought the HPV vaccine should not be mandated, even 
though 97 percent of physicians believed that the HPV vaccine should 
be administered.
153
 
In addition to the lack of unity among physicians regarding 
mandatory HPV vaccination, an even greater concern is that, while 
physicians may have their patients’ health in mind, they are nonetheless 
susceptible to aggressive marketing tactics by large pharmaceutical and 
biotechnology companies. Nowhere has this been truer than with 
Merck’s hard-lined and novel marketing campaign for Gardasil®. 
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Merck started by cherry-picking its disease. Fearing parent 
opposition to a vaccine that immunized against sexually transmitted 
disease, Merck chose instead to focus on HPV’s implications for 
cervical cancer,
154
 and what parent would not want to protect his or her 
daughter against cancer? Merck next appealed to a broad audience. 
Rather than focus on highly susceptible populations, Merck 
indiscriminately targeted every adolescent girl in America, inspiring 
them to be “1 less” victim of cervical cancer.
155
 Merck successfully 
made the HPV vaccine into a sensation, so much so that, in 2007, 
shortly after the FDA approved Gardasil®, Pharmaceutical Executive 
rewarded Gardasil® the “Brand of the Year” for having created a 
“market out of thin air.”
156
 
Merck understood that the best method for reaching individual 
consumers was through physicians, and it further realized that 
physicians follow recommendations from professional medical 
associations.
157
 Thus began a directed campaign by Merck to heighten 
associations’ involvement in vaccine promotion.
158
 Merck provided 
professional medical associations with funding, which these 
associations then used for educational programs and Gardasil®-specific 
speakers’ bureaus.
159
 Unsurprisingly, these educational programs and 
speakers’ bureaus were one-sided, often omitting critical information 
necessary for physicians to accurately determine if administering the 
vaccine is best for their patients.
160
 Furthermore, Merck required these 
associations to report back to it with progress updates.
161
 
Merck specifically targeted the following professional medical 
associations: the American College of Obstetricians and Gynecologists, 
the American Society for Colposcopy and Cervical Pathology 
(ASCCP), the Society of Gynecologic Oncologists (SGO), and the 
American College Health Association (ACHA).
162
 Each association in 
turn developed a unique program with Merck’s donated funds. For 
example, ASCCP developed an “Educate the Educators” program that 
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taught physicians how to educate the public about the vaccine.
163
 Each 
physician who attended the program received a “Speaker Lecture Kit” 
that provided a set of educational tools, including a 173-slide 
PowerPoint presentation.
164
 The slideshow urged physicians to contact 
local and state governments about funding the vaccine, encouraging 
insurance companies to cover the vaccine, and mandating the vaccine.
165
 
The slideshow further advocated that physicians avoid discussing the 
sexually transmitted aspect of HPV, if they feel that parents would be 
uncomfortable doing so.
166
 
The SGO similarly developed a program that provided 
incomprehensive, biased information to physicians. The SGO started an 
HPV vaccine speakers’ bureau, which was comprised of panelists who 
were financially connected to Merck and who drafted all of the lecture 
materials.
167
 The speaker series puffed up the HPV vaccine’s notoriety as 
“the first vaccine directed against a cancer,” while completely ignoring 
the cautionary details.
168
 For example, the teaching materials failed to 
provide comprehensive data on cervical cancer incidence rates and 
declined to discuss secondary prevention methods, safety and efficacy 
data, and potential risks.
169
 
Nowhere in any of the educational materials produced by these 
professional medical associations did these associations mention their 
connection to Merck or that Merck was funding their efforts.
170
 This lack 
of transparency is disconcerting because it shows that these associations 
are either being blindly manipulated or willingly eating out of the hands 
of their donors, knowing that public health and safety may be at risk. 
If professional medical associations are so willing to act as pawns 
for the pharmaceutical industry, then they are ill-suited to make 
recommendations to states regarding compulsory vaccination laws. 
Professional medical associations should not be engaging in product-
specific speakers’ bureaus or reporting their educational activity to 
Merck (or any other industry donor).
171
 As their mission statements 
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suggest, professional medical associations should be dedicated to 
disseminating unbiased, scientifically-backed information that benefits 
patients, not pharmaceutical companies.
172
 If associations can achieve 
those ends, then perhaps they will emerge as authorities on state 
compulsory vaccination laws. 
VII.  ACCOUNTABILITY: HOW DO WE HOLD FEDERAL 
AGENCIES RESPONSIBLE FOR MANDATORY VACCINATION 
LAWS? 
This Article has proposed the idea of shifting decision-making 
behind compulsory vaccination laws from state legislatures to another 
entity, such as the FDA or the CDC. Both the CDC and FDA are armed 
with a greater level of vaccine knowledge and familiarity than a state 
legislature could ever hope to glean. Yet passing the buck from state 
legislatures to federal agencies elicits discomfort because inevitably, 
granting greater authority to a federal agency (like the FDA or CDC) 
means stripping state legislatures of power. Part of this discomfort 
stems from the federalist tradition that residual power in the United 
States is reserved for the states.
173
 
As a democratic republic, the power of the government rests in the 
hands of the United States citizens. 
174
 More specifically, through voting, 
the public is able to hold incumbents accountable for the policy 
decisions they make.
175
 As a result, incumbents work to respond to the 
public’s interests and demands, and thus, public interests shape public 
policy.
176
 In the case of compulsory vaccination laws, incumbent 
accountability is a very attractive privilege because if a state legislature 
makes a decision regarding public health that is contrary to the public 
interest, the public is able to resolve the problem via the ballot box. In 
summary, the public has recourse through the electoral process. 
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This type of accountability does not exist with federal agencies, at 
least not to the same extent that state legislatures can be held 
accountable.
177
 Some argue that there is Presidential accountability.
178
 In 
other words, if an individual citizen has an issue with an action taken by 
an administrative agency, he or she can raise that issue in the next 
Presidential election. However, the relationship between the President’s 
accountability and for example, the Secretary of the Department of 
Health and Human Service’s accountability seems attenuated at best and 
hardly satisfactory. This is particularly apparent to the mother whose 
daughter has just been ordered to receive the HPV vaccine before she is 
permitted to enter the sixth grade. 
That said, perhaps compulsory vaccination laws fit well within the 
area of lawmaking for which federal agencies were designed. Courts 
and commentators have argued that “agencies are better situated to 
address technical and scientific issues on the ‘frontiers of science,’”
179
 
and in fact, agencies originated with one strength in mind: expertise in 
particular policy areas that are uniquely technical.
180
 In effect, agencies 
exist for the very purpose of providing the expertise that legislatures 
lack.
181
 This specialization is reflected in agency structures, which have 
a small staff of appointed officials coupled with a large staff of 
technological and scientific experts.
182
 
Although agencies may have little direct accountability, that 
problem can be mitigated. Congress can exert additional authority over 
administrative agencies by shaping their authoritative boundaries 
through legislation.
183
 Additionally, accountability can be assured 
through proper oversight.
184
 
Administrative law is a complex area, and this Article does not 
provide a solution to the question of whether a federal agency or a state 
legislature is better adapted to decide if a given compulsory vaccination 
law should be passed. However, addressing the issue of accountability 
highlights the need to take administrative law into consideration when 
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determining who should be making compulsory vaccination laws. 
 
CONCLUSION 
The HPV vaccine stands front and center in a long line of vaccines 
for which compulsory vaccination will be proposed and subsequently 
debated. The HPV vaccine is not unique in its controversy; it is only the 
first of many vaccines that exist in a type of purgatory where 
compulsory vaccination is not obvious, but at the same time, is not 
completely implausible either. 
With the rapid development of science and technology, drug and 
biologic manufacturers will continue to discover vaccines for a myriad 
of different diseases, ranging from the most contagious to the 
completely incommunicable, from the severely life-threatening to the 
borderline innocuous. As it stands, the current process inadequately 
deals with those vaccines that do not fit squarely into the protocol 
defined in Jacobson. 
Currently, state legislatures have seemingly limitless power to 
mandate vaccines, even when they are neither contagious nor largely 
life-threatening. What is more concerning is that state legislatures’ 
decisions seem largely driven by social and economic demands that 
they readily succumb to in an effort to earn constituent votes. Should 
compulsory HPV vaccine laws be upheld, there is the possibility that 
vaccination policy will cascade down a slippery slope, at the bottom of 
which state legislatures have the ability to strip individuals of their 
privacy rights for unwarranted public health policies. 
Somehow, the current system must be cleansed of its biases, but at 
the same time, no suitable substitute appears readily available. It seems 
that government agencies and professional medical associations are 
haunted by similar industry pressures as state legislatures. To delegate 
authority to the CDC, for example, may only serve to perpetuate biased 
decision-making when it comes to compulsory vaccination laws. At the 
same time, the CDC and the FDA are bastions of expertise and 
knowledge that could prove instrumental in shifting the focus of vaccine 
law from socio-economic concerns to scientific-technical concerns. 
Perhaps the solution is to foster more collaboration between federal 
agencies and state legislatures rather than to provide single-handed 
authority to either entity. Instead of the CDC and ACIP disseminating 
isolated recommendations upon which state legislatures must 
impetuously rely, the CDC and state legislatures could collaborate to 
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develop comprehensive legislation drafted with the perspectives of 
multiple disciplines in mind. After all, most states already adhere to 
CDC recommendations, so making the process more informed would 
only serve to bolster the quality of state legislation. 
For clarification, this Article does not make any conclusions as to 
whether the HPV vaccine should be mandatory in international settings. 
Certainly, the need for the government to protect public health and 
safety may be greater in areas where access to medical attention 
(including secondary prevention methods, such as the Pap smear) is 
limited, where gender discrimination prohibits adequate reproductive 
health care, and where cost (especially with on-patent drugs) is a 
limiting factor for individuals in making health care decisions. The topic 
of international mandatory vaccination is reserved for future discussion. 
Further, this Article does not condemn the HPV vaccine. On the 
contrary, this Article supports the determinations of the FDA, CDC, and 
ACIP, which recommend the HPV vaccine where appropriate. 
However, this Article does advocate for sound public health policies 
that are not motivated by politics or bureaucracy but instead find their 
basis in rigorous and legitimized scientific study and assessment. State 
representatives’ inability to objectively assess the HPV vaccine has 
undermined the vaccine’s immense potential health benefits and 
distracted law-makers from their true obligations: to make decisions that 
are in the best interest of the public health and safety. 
 
